NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis $7.31 -0.40 (-5.19%) Closing price 04:00 PM EasternExtended Trading$7.32 +0.01 (+0.07%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ClearPoint Neuro Stock (NASDAQ:CLPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ClearPoint Neuro alerts:Sign Up Key Stats Today's Range$7.25▼$7.9550-Day Range$7.31▼$15.7952-Week Range$7.25▼$19.63Volume704,764 shsAverage Volume714,779 shsMarket Capitalization$234.29 millionP/E RatioN/ADividend YieldN/APrice Target$24.33Consensus RatingHold Company Overview ClearPoint Neuro develops technologies used to plan, guide and monitor minimally invasive procedures in the brain and spine. Its product portfolio includes MRI-guided navigation systems and instruments for neurosurgery, including tools for laser ablation and for delivering therapeutics to targeted areas of the central nervous system. The company also works with biotechnology and pharmaceutical partners on the delivery of cell and gene therapies and other biologics to the brain. Its platforms are designed to support accurate placement and monitoring during procedures and in clinical research. ClearPoint Neuro was formerly known as MRI Interventions and adopted its current name in 2020. The company serves hospitals, research institutions and industry partners in the United States and internationally.AI Generated. May Contain Errors. Read More ClearPoint Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreCLPT MarketRank™: 1.98027937551 of 5 starsClearPoint Neuro scored higher than 40% of companies evaluated by MarketBeat, and ranked 630th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingClearPoint Neuro has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialClearPoint Neuro has a consensus price target of $24.33, representing about 232.9% upside from its current price of $7.31.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 2 research reports in the past 90 days.Read more about ClearPoint Neuro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($1.17) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 8.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.40% of the float of ClearPoint Neuro has been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 6.56.Change versus previous monthShort interest in ClearPoint Neuro has recently decreased by 7.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for CLPT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.Percentage Held by Insiders6.94% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by Institutions30.08% of the stock of ClearPoint Neuro is held by institutions.Read more about ClearPoint Neuro's insider trading history. Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLPT Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTNovember 12, 2026 | prnewswire.comClearPoint Neuro (CLPT) AI Stock AnalysisNovember 11, 2026 | tipranks.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 19 at 1:00 AM | Base Camp Trading (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTNovember 10, 2026 | globenewswire.comClearPoint Neuro: Momentum Building Across The BusinessNovember 9, 2026 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTNovember 5, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTNovember 3, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTOctober 29, 2026 | prnewswire.comSee More Headlines CLPT Stock Analysis - Frequently Asked Questions How have CLPT shares performed this year? ClearPoint Neuro's stock was trading at $13.68 at the beginning of 2026. Since then, CLPT stock has decreased by 46.6% and is now trading at $7.31. How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) posted its quarterly earnings data on Wednesday, October, 28th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.08. The firm earned $12.08 million during the quarter, compared to analyst estimates of $12.30 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 170.24% and a negative net margin of 79.43%. Read the conference call transcript. Who are ClearPoint Neuro's major shareholders? ClearPoint Neuro's top institutional investors include State Street Corp (2.73%), Marshall Wace LLP (1.66%), Goldman Sachs Group Inc. (1.09%) and Pekin Hardy Strauss Inc. (0.87%). Insiders that own company stock include Joseph Burnett, Timothy T Richards, Lynnette C Fallon and Matthew B Klein. View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ClearPoint Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Palantir Technologies (PLTR), Block (XYZ), NVIDIA (NVDA), TransMedics Group (TMDX), Trade Desk (TTD), Stem (STEM) and Super Micro Computer (SMCI). Company Calendar Last Earnings10/28/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CLPT's financial health is in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:CLPT CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees172Year Founded1998Price Target and Rating Average Price Target for ClearPoint Neuro$24.33 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+232.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.54 million Net Margins-79.43% Pretax Margin-79.50% Return on Equity-170.24% Return on Assets-37.00% Debt Debt-to-Equity Ratio1.86 Current Ratio6.76 Quick Ratio5.77 Sales & Book Value Annual Sales$36.97 million Price / Sales6.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book8.60Miscellaneous Outstanding Shares32,050,000Free Float29,829,000Market Cap$234.29 million OptionableOptionable Beta1.38 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CLPT) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.